

Solange Moréra,^{a*} Virginie
Gueguen-Chaignon,^a Aurélie
Raffoux^b and Denis Faure^b^aLaboratoire d'Enzymologie et de Biochimie
Structurales, CNRS, F-91198 Gif-sur-Yvette
CEDEX, France, and ^bInstitut des Sciences du
Végétal, CNRS, F-91198 Gif-sur-Yvette CEDEX,
France

Correspondence e-mail: morera@lebs.cnrs-gif.fr

Received 10 October 2008

Accepted 6 November 2008

Cloning, purification, crystallization and preliminary X-ray analysis of a bacterial GABA receptor with a Venus flytrap fold

In response to infection by the pathogen *Agrobacterium tumefaciens*, plants synthesize several stress amino acids, including γ -aminobutyric acid (GABA), which modulates the expression of bacterial virulence factors. GABA penetrates into the bacterial cytoplasm *via* an ABC transporter that is associated with the periplasmic receptor Atu2422. Mature receptor Atu2422 (without its signal peptide) was overexpressed in *Escherichia coli*, purified and crystallized. A complete data set was collected to 1.35 Å resolution at 100 K. The crystals belonged to the monoclinic space group C2 and contained one molecule in the asymmetric unit. Molecular replacement was performed and the initial electron-density maps revealed a closed form of this Venus flytrap (VFT) receptor, suggesting the presence of an endogenous *E. coli* ligand.

1. Introduction

The pathogen *Agrobacterium tumefaciens* is responsible for crown gall disease in numerous plants of agronomical interest (reviewed by Escobar & Dandekar, 2003). Several plant signals are required to control the expression of virulence. γ -Aminobutyric acid (GABA) acts as a plant signal that attenuates virulence functions by inducing the expression of the lactonase AttM in *A. tumefaciens* (Chevrot *et al.*, 2006; Yuan *et al.*, 2008). This lactonase can cleave the bacterial signal 3-oxooctanoyl homoserine lactone (OC8HSL) when *A. tumefaciens* colonizes the plant tissues. Therefore, it may affect the expression of OC8HSL-dependent functions, such as the dissemination of virulence genes by horizontal transfer of the tumour-inducing (Ti) plasmid (Zhang *et al.*, 2002) and the number of emerging tumours at the infection site (Chevrot *et al.*, 2006).

The import of GABA into several bacteria requires a periplasmic bacterial receptor that traps the GABA molecule and transfers it to the ABC transporter Bra. The GABA receptor is called Atu2422 in *A. tumefaciens* strain C58 (Chevrot *et al.*, 2006) and BraC (RI3745) in *Rhizobium leguminosarum* bv. *viciae* strain 3841 (Hosie *et al.*, 2002). The peptide sequence of Atu2422 shares around 40% sequence identity with two *Escherichia coli* periplasmic amino-acid receptors of known structure: Leu-Ile-Val-binding protein (LIVBP, LivJ; Sack, Saper *et al.*, 1989; Trakhanov *et al.*, 2005) and leucine-binding protein (LBP, LivK; Sack, Trakhanov *et al.*, 1989; Magnusson *et al.*, 2004). These amino-acid receptors, which consist of two domains separated by a deep cleft, exhibit the Venus flytrap (VFT) architecture, which is conserved among a large number of ligand-binding proteins in bacteria and eukaryotes, including the GABA_B receptors in mammals (Galvez *et al.*, 1999), as shown by modelling based on sequence alignment (Acher & Bertrand, 2005). The unliganded receptor adopts an open form, whereas it adopts a closed form upon ligand binding.

Here, we report the successful purification, crystallization and preliminary X-ray analysis of the bacterial GABA receptor Atu2422.

2. Cloning, expression and purification

Genomic DNA purified from *A. tumefaciens* strain C58 was used as a template to amplify the DNA encoding the mature protein Atu2422



(consisting of 349 residues without its signal peptide). Suitable restriction sites (*NdeI* and *NotI*; shown in bold) were added to the primers (5'-GGAATT**CCATATGG**GATGTCGTCATCGCTGTC and 5'-TTT**GCGGCCG**CTTAATGGT**GATGGT**GATGGTGGCTGCC-CTGCTGG) for cloning into a pET-9aSN1 expression vector (a gift from S. Chéruef, IBBMC, University Paris Sud, Orsay, France). An oligonucleotide coding for a six-histidine tag was added to the 3' end of the gene to facilitate protein purification.

The PCR product was purified with a QIAquick PCR purification kit (Qiagen), digested with *NdeI* and *NotI* enzymes and cloned into the expression vector pET-9aSN1, which was digested with the same enzymes. The construct was then introduced by heat shock into XL1-Blue chemically competent cells. The nucleotide sequence of one selected clone was confirmed by DNA-sequence analysis.

For the expression of Atu2422 (residues 24–372)-6×His, transformed BL21 (DE3) STAR *E. coli* cells were grown at 310 K to an OD₆₀₀ of about 0.8 in 2×TY medium containing 50 µg ml⁻¹ kanamycin. Expression of the His-tagged receptor was induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside. The cells were grown for a further 3 h at 310 K before centrifugation (4000g, 10 min). The pellet was resuspended in 25 mM Tris-HCl pH 8.5, 150 mM NaCl. Cell lysis was achieved by sonication after the addition of an anti-protease cocktail (Sigma). Cell debris was spun out by centrifugation at 40 000g for 30 min at 277 K. Recombinant mature protein with a C-terminal His tag (Atu2422-His) was purified by IMAC chromatography using Ni-NTA resin (Qiagen) equilibrated in 25 mM Tris-HCl pH 7.5, 300 mM NaCl, 10 mM imidazole. Low-affinity binding contaminants were washed from the column with 35 mM imidazole prior to the elution of Atu2422 with 300 mM imidazole. The eluted sample was further purified by size-exclusion chromatography using a Superdex 200 HiLoad column (Amersham Biosciences) equilibrated in 20 mM HEPES pH 7.5, 150 mM NaCl. Both chromatographic steps were performed on an ÄKTA Purifier 10 (Amersham Biosciences) at 277 K. The purity of the sample was determined by SDS-PAGE. Atu2422-His was concentrated to 11 mg ml⁻¹ using Vivaspinn-10 centrifugal concentrators (Vivasciences) and stored frozen.

3. Crystallization

In crystallization trials, mature Atu2422-His protein was used at a concentration of 11 mg ml⁻¹ in a buffer consisting of 20 mM HEPES pH 7.5 and 150 mM NaCl. Commercial crystallization kits (the PEG II and Classics Suites from Qiagen) were screened in sitting-drop vapour-diffusion experiments using a nanodrop robot (Cartesian Proteomic Solutions) at 293 K. Small crystals appeared within 3 d in only one condition (PEG II condition D4). Crystallization conditions



Figure 1
Large thin plate-shaped crystals of Atu2422 (dimensions 0.6 × 0.1 × 0.04 mm).

Table 1
Data-collection statistics.

Values in parentheses are for the highest resolution shell (of nine).

Space group	C2
Unit-cell parameters (Å, °)	$a = 116.2, b = 38.9,$ $c = 71.6, \beta = 95.7$
Resolution (Å)	30.0–1.35 (1.42–1.35)
No. of observed reflections	283328
No. of unique reflections	69760
Completeness (%)	99 (98.2)
$R_{\text{merge}}^{\dagger}$ (%)	7.3 (68)
$I/\sigma(I)$	13 (2.1)

$\dagger R_{\text{merge}} = \frac{\sum_{hkl} \sum_i |I_i(hkl) - \langle I(hkl) \rangle|}{\sum_{hkl} \sum_i I_i(hkl)}$, where $I_i(hkl)$ is the i th observed amplitude of reflection hkl and $\langle I(hkl) \rangle$ is the mean amplitude for all observations i of reflection hkl .

were then manually optimized with home-made solutions. 2 µl protein solution was mixed with 2 µl reservoir solution consisting of 0.1 M Tris-HCl pH 8.5, 35% (w/v) PEG 4000, 100 mM CaCl₂ and equilibrated over 1 ml reservoir solution, leading to large thin plate-shaped crystals (Fig. 1).

4. Data collection and processing

Crystals were flash-frozen in a cryoprotectant solution containing 0.1 M Tris-HCl pH 8.5, 37% PEG 4000, 100 mM CaCl₂ and 20% glycerol. Data-collection experiments were carried out at 100 K on the PROXIMA I beamline at SOLEIL (Saint Aubin, France). 360° of data were collected in 1° frames, with 1 s exposure per frame. Diffraction intensities were evaluated with the program XDS (Kabsch, 1993) and further processed using the CCP4 program suite (Collaborative Computational Project, Number 4, 1994). The crystal diffracted to 1.35 Å resolution and belonged to the monoclinic space group C2, with unit-cell parameters $a = 116.2, b = 38.9, c = 71.6$ Å, $\beta = 95.7^\circ$. Data-collection and processing statistics are given in Table 1.

5. Molecular replacement

The asymmetric unit can contain only one molecule, corresponding to a Matthews coefficient (Matthews, 1968) of 2.15 Å³ Da⁻¹ and a solvent content of 42.9%. Molecular replacement using the program Phaser (Storoni *et al.*, 2004) gave an incorrect solution (RFZ = 5.2, TFZ = 2.8, LLG = -70 and an initial R factor of 51%) using the apo structure of *E. coli* LBP (PDB code 1usg) as a search model. Taking into account the fact that periplasmic amino-acid receptors are known to bind endogenous amino acids during the production/purification procedure (Trakhanov *et al.*, 2005; Huvent *et al.*, 2006), a liganded form of LBP (PDB code 1usk; leucine-bound) was used as a model and led to a solution with good scores (RFZ = 9.5, TFZ = 10.2, LLG = 158) and an initial R factor of 44%. Examination of the resulting model and density maps clearly showed that Atu2422 adopts a closed conformation, meaning that the receptor was crystallized with a bound fortuitous ligand that needs to be identified. Refinement of the mature receptor Atu2422 structure and determination of its amino-acid selectivity are under way.

We are grateful to Andrew Thompson for help in data collection on PROXIMA I. We thank Véronique Henriot for the expression test, which was realised on the LEBS cloning/protein-expression facility. The crystallization work benefitted from the LEBS facilities

of the IMAGIF Structural Biology and Proteomic Unit at the Gif campus (<http://www.imagif.cnrs.fr>).

References

- Acher, F. C. & Bertrand, H. O. (2005). *Biopolymers*, **80**, 357–366.
- Chevrot, R., Rosen, R., Haudecoeur, E., Cirou, A., Shelp, B. J., Ron, E. & Faure, D. (2006). *Proc. Natl Acad. Sci. USA*, **103**, 7460–7464.
- Collaborative Computational Project, Number 4 (1994). *Acta Cryst.* **D50**, 760–763.
- Escobar, M. A. & Dandekar, A. M. (2003). *Trends Plant Sci.* **8**, 380–386.
- Galvez, T., Parmentier, M. L., Joly, C., Malitschek, B., Kaupmann, K., Kuhn, R., Billiger, H., Froestl, W., Bettler, B. & Pin, J. P. (1999). *J. Biol. Chem.* **274**, 13362–13369.
- Hosie, A. H., Allaway, D., Galloway, C. S., Dunsby, H. A. & Poole, P. S. (2002). *J. Bacteriol.* **184**, 4071–4080.
- Huvent, I., Belrhali, H., Antoine, R., Bompard, C., Loch, C., Jacob-Dubuisson, F. & Villeret, V. (2006). *Acta Cryst.* **D62**, 1375–1381.
- Kabsch, W. (1993). *J. Appl. Cryst.* **26**, 795–800.
- Magnusson, U., Salopek-Sondi, B., Luck, L. A. & Mowbray, S. L. (2004). *J. Biol. Chem.* **279**, 8747–8752.
- Matthews, B. W. (1968). *J. Mol. Biol.* **33**, 491–497.
- Sack, J. S., Saper, M. A. & Quijoch, F. A. (1989). *J. Mol. Biol.* **206**, 171–191.
- Sack, J. S., Trakhanov, S. D., Tsigannik, I. H. & Quijoch, F. A. (1989). *J. Mol. Biol.* **206**, 193–207.
- Storoni, L. C., McCoy, A. J. & Read, R. J. (2004). *Acta Cryst.* **D60**, 432–438.
- Trakhanov, S., Vyas, N. K., Luecke, H., Kristensen, D. M., Ma, J. & Quijoch, F. A. (2005). *Biochemistry*, **44**, 6597–6608.
- Yuan, Z. C., Haudecoeur, E., Faure, D., Kerr, K. F. & Nester, E. W. (2008). *Cell Microbiol.* **10**, 2339–2354.
- Zhang, H. B., Wang, L. H. & Zhang, L. H. (2002). *Proc. Natl Acad. Sci. USA*, **99**, 4638–4643.